{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T22:55:28Z","timestamp":1752101728620},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1689","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza for the 2023-2024 season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov\/flu.<\/jats:p>","DOI":"10.58347\/tml.2023.1689a","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:17:28Z","timestamp":1700579848000},"page":"177-182","source":"Crossref","is-referenced-by-count":1,"title":["Antiviral Drugs for Influenza for 2023-2024"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,11,13]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:17:28Z","timestamp":1700579848000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1689a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":0,"journal-issue":{"issue":"1689","published-online":{"date-parts":[[2023,11,13]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1689a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]}}}